In conclusion, the current systematic review and meta‐analysis indicate that curcumin therapy could potentially decrease ALT and AST in NAFLD patients, with no significant changes in ALP. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.